A comparative study on efficacy and safety of 3D conformal radiotherapy with three doses for patients with stage Ⅲ esophageal cancer(PDF)
《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]
- Issue:
- 2020年第12期
- Page:
- 1494-1497
- Research Field:
- 医学放射物理
- Publishing date:
Info
- Title:
- A comparative study on efficacy and safety of 3D conformal radiotherapy with three doses for patients with stage Ⅲ esophageal cancer
- Author(s):
- ZHANG Cuicui; LU Xiaojun; ZHAO Jing
- The First Affiliated Hospital of Air Force Medical University, Xian 710032, China
- Keywords:
- esophageal cancer 3D conformal radiotherapy radiotherapy dose concurrent chemoradiotherapy efficacy safety
- PACS:
- R811.1；R735.1
- DOI:
- DOI:10.3969/j.issn.1005-202X.2020.12.004
- Abstract:
- Objective To compare the efficacy and safety of three-dose 3D conformal radiotherapy (3D-CRT) for patients with stage III esophageal cancer. Methods 99 esophageal cancer patients who were treated with concurrent radiotherapy and chemotherapy from January 2016 to March 2018 were retrospectively selected and randomly divided into low, medium, and high dose groups, with 33 cases in each group. Each group was respectively given 3D-CRT 54, 62, and 68 Gy and concurrent chemotherapy. The short-term efficacy, long-term survival status and safety of the three groups were compared. Results There was no tumor progression in all patients after 2 months of radiotherapy, and the disease control rate reached 100%. The objective response rate of the low-dose group was significantly lower than that of the high-dose group (P<0.05). All patients were followed up regularly. As of May 2020, the median follow-up time was 20.5 months (2.5-49.5 months), and the median overall survival time (OS) in the low, medium, and high dose groups was 15.16 months, (95% CI: 8.33-22.89), 28.06 months (95% CI: 13.98-42.09), and 23.33 months (95% CI: 10.06-36.80) respectively. The median OS of the middle-dose group was significantly higher than that of the low-dose group (P<0.05). In terms of safety, none of the patients had serious complications such as esophageal perforation, radiation myelitis, but the bone marrow suppression was the most common adverse reaction in the three groups. The incidence of radiation esophagitis in the low-dose group was significantly lower than that of the high-dose group (P<0.05). Conclusions For patients with stage III esophageal cancer with concurrent radiotherapy and chemotherapy, the 3D-CRT 62 Gy has the best comprehensive effect, with satisfactory short-term efficacy and long-term survival time, and high safety.
Last Update: 2020-12-30